Your SlideShare is downloading. ×
0
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Graham Hughes - Beta Technology - FP 7 Call Presentation
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Graham Hughes - Beta Technology - FP 7 Call Presentation

1,146

Published on

Published in: Technology, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
1,146
On Slideshare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
6
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide
  • Introduce myself work for Beta Technology contracted to TSB to provide the NCP service for the UK (Health) NCP role support for institutions wanting to access EU funding through the framework programme. publicity, advice, support, facilitation Ascertain how many have heard of Framework program
  • So how is the Framework Program structured? First of all it is broken down into the major themes. Cooperation : the one we are most interested in and the core of FP7. It is designed to foster collaborative research across Europe and other partner countries through funded projects performed by transnational consortia of industry and academia Ideas: this theme supports frontier research solely on the basis of scientific excellence. Covers any area of science and technology, including socio-economic sciences and humanities. No obligation for cross-border partnerships – projects performed around individual teams. Implemented under the new European Research Council People : provides support for researcher mobility and career development both within the EU and internationally. Can provide initial training, industry-academia partnerships, funding of regional, national and international mobility programs. Capacities : designed to strengthen the research capacities that Europe needs to become a knowledge based economy. Programmes support research infrastructure with specific funding of projects by SMEs across a wide range of disciplines. Nuclear Research : lumps together all nuclear research including fusion energy, radiation protection, nuclear waste, support for EU policy making
  • Let’s now focus on the Cooperation Theme, which attracts 60% of all Framework funding. It is broken down into ten different Program areas, each of which is allocated its own budget. Can see that the two biggest tranches of money are given to ICT and Health. Research activities in all these Program areas are driven by yearly “top down” calls for projects which describe specific topics and research areas. Projects are invited from trans-national consortia that meet the scope of the individual topic areas. There are, unfortunately a complex set of rules that these projects must follow, based around the project type, the construction of the consortium and the specific funding scheme that is determined for each subject. Not going to go into that detail now. A portion of the budget allocation for each programme is allocated with each call, for example this year the Health call was worth €651 million
  • So what are the benefits of participation? There are a number, as shown here. Access to new networks and contacts – once in a consiortium can leverage the additional networks from other partners Money, obviously. Funding of a project could release resources for other activities. Profile ; increased visibility across the European stage could lead to further opportunities.
  • So what are the benefits of participation? There are a number, as shown here. Access to new networks and contacts – once in a consiortium can leverage the additional networks from other partners Money, obviously. Funding of a project could release resources for other activities. Profile ; increased visibility across the European stage could lead to further opportunities.
  • Again, the aim is to promote co-operation both trans-nationally within Europe and internationally so the programmes are usually open to a wide range of countries: EU Member States – have broadest rights and access Associated Countries, those with close associations with EC or seeking membership ICPCs – specific countries or groups of countries that receive preference for specific call topics Industrialised high income countries can participate but generally these will be expected to finance themselves The funding structure of the individual calls will specify specific conditions depending upon the nature of the topic but the basic rule is that there should be a minimum of three different legal entities from three different member states making up the core of the consortium.
  • Again, the aim is to promote co-operation both trans-nationally within Europe and internationally so the programmes are usually open to a wide range of countries: EU Member States – have broadest rights and access Associated Countries, those with close associations with EC or seeking membership ICPCs – specific countries or groups of countries that receive preference for specific call topics Industrialised high income countries can participate but generally these will be expected to finance themselves The funding structure of the individual calls will specify specific conditions depending upon the nature of the topic but the basic rule is that there should be a minimum of three different legal entities from three different member states making up the core of the consortium.
  • Introduce myself work for Beta Technology contracted to TSB to provide the NCP service for the UK (Health) NCP role support for institutions wanting to access EU funding through the framework programme. publicity, advice, support, facilitation Ascertain how many have heard of Framework program
  • Introduce myself work for Beta Technology contracted to TSB to provide the NCP service for the UK (Health) NCP role support for institutions wanting to access EU funding through the framework programme. publicity, advice, support, facilitation Ascertain how many have heard of Framework program
  • Always informative to see what factors are driving the direction of the WP Part of the Europe 2020 growth strategy with 5 key targets 75% of 20 – 64 age group in employment 3% GDP spent on R&D Greenhouse gas emissions 20% lower than 1990 School drop out rates < 10% 20 million fewer people in poverty The Innovation Union aims to improve conditions and access to finance for research and innovation in Europe, to ensure that innovative ideas can be turned into products and services that create growth and jobs.
  • Starred topic areas have been closed for two successive calls
  • Going to cover call topics by sub theme and call priority. Some will fall into two or even three categories so may repeat Don’t have time to go through each one in detail. If you identify any that you are interested in make a note then contact me or Vic to get details or discuss in detail.
  • Emphesise 100% two stage call
  • Transcript

    • 1. FP7 2012 Health Call Overview Graham Hughes, FP7UK NCP for Health (Industry)
    • 2. <ul><li>“ FP7 work programmes will “ continue to secure world excellence in basic research ” through large scale collaborative research efforts </li></ul><ul><li>JM Barroso 2009 </li></ul>
    • 3. FP7 - €53 billion spend 2007 - 2013
    • 4. Cooperation Theme
    • 5. Cooperation Theme Basics <ul><li>Top down process, yearly call for proposals based around specific topic areas </li></ul><ul><li>Projects performed by consortia of academic/industry/ public sector participants </li></ul><ul><li>Matched funding (EU contributes to total cost of project) </li></ul><ul><li>Participants sign legal contract with the EU </li></ul>
    • 6. <ul><li>Three Major Objectives </li></ul><ul><li>Improve the health of European citizens </li></ul><ul><li>Boost the competitiveness of health related industries </li></ul><ul><li>Address global health issues </li></ul><ul><li>Also seeking to implement research objectives that help to realise the aims of the Innovation Union (Europe 2020) flagship initiative . </li></ul>Health Theme Objectives
    • 7. The Health Theme: Structure Activity 1: Biotechnology, generic tools &amp; technologies for health Activity 2: Translating research for human health Activity 3: Optimising the delivery of health care cross-cutting issues: international cooperation, SMEs, child health, ageing populations, gender -related health issues Activity 4: Support actions &amp; response to policy needs The Innovative Medicines Initiative
    • 8. Health Theme Funding 2007 - 2013 Year Total Funding Projects Funded 2007 € 641 million 153 2008 € 577 million 172 2009 € 611 million 105 2010 € 621 million 131 2011 € 650 million ~126 2012 € 620 million ? 2013 € 780 million ?
    • 9. UK Performance (Health Theme) Health Funding totals 2007 -2009 – All Participations
    • 10. UK FP7 Health Theme in Numbers* Submissions with UK partners = 3264* Successful projects with UK partners = 859 UK coordinated submissions = 383 93 projects coordinated by UK partners *2007 – 2009 data – from GAs and participants database (released on 1 May 2010 - data cut-off date 25 March 2010 52 UK SMEs in active FP7 projects (plus 17 new 2010)
    • 11. SME Participation EU target of 15% funding to SME partners
    • 12. <ul><li>Access significant research funding </li></ul><ul><li>75% RTD costs and 100% management and training costs </li></ul><ul><li>EU contribution between €2 and 12 million </li></ul><ul><li>Overhead rate for HEIs and SMEs = 60% </li></ul><ul><li>Strengthening Research Capabilities </li></ul><ul><li>Increased collaboration between basic and clinical researchers, regulatory bodies and patient groups </li></ul><ul><li>Access to new networks and contacts </li></ul><ul><li>develop new business contacts from the linkages formed in a consortium </li></ul><ul><li>Access to IP and facilities otherwise unavailable </li></ul><ul><li>Elevated Profile </li></ul><ul><li>Publications, CORDIS </li></ul>Collaborative Research: Why?
    • 13. Collaborative Research: Who? <ul><li>Countries </li></ul><ul><li>EU Member States – broadest rights and access </li></ul><ul><li>Associated Countries – e.g. Iceland, Norway, Turkey, Israel </li></ul><ul><li>International Cooperation Partner Countries (ICPC) – e.g. Russia, Central Asian, Balkan, North African countries </li></ul><ul><li>Industrialised high-income countries (e.g Australia, Korea, Japan) – self financing. USA has reciprocal arrangement </li></ul><ul><li>Co-operation with “third countries” explicitly encouraged in FP7 </li></ul><ul><li>Organisations </li></ul><ul><li>research groups at universities or research institutes </li></ul><ul><li>innovative companies (SMEs and larger) </li></ul><ul><li>public or governmental administration (eg NHS trusts) </li></ul><ul><li>Charities and other not for profit organisations </li></ul>
    • 14. <ul><li>Build consortium : </li></ul><ul><ul><li>3 legal entities from minimum of 3 EU Member states or Associated Countries </li></ul></ul><ul><ul><li>Other partners added per requirements of project/partner mix </li></ul></ul><ul><ul><li>Some other special eligibility criteria may apply – read call document carefully </li></ul></ul><ul><li>Match project with the topic </li></ul><ul><ul><li>Seek advice if not sure </li></ul></ul><ul><ul><li>Funding level is indicative of project scope </li></ul></ul><ul><ul><li>Pay attention to expected outcome – European scope </li></ul></ul><ul><li>Follow rules for submission (EPSS) </li></ul>Collaborative Research: How?
    • 15. WP First Draft Open day (Brussels) 09 June 2011 Call published Stage 1 Deadline NCP Roadshow Evaluation results Evaluation PC Meetings Collaborative Research: When?
    • 16. Framework Programme 7 Support and Further Information Graham Hughes, FP7UK NCP for Health (Industry)
    • 17. Initial Considerations <ul><li>Are you ready for participation? </li></ul><ul><ul><li>Does it fit your aspirations/business plan </li></ul></ul><ul><ul><li>Collaborative projects mean working alongside international partners. </li></ul></ul><ul><ul><ul><li>Does this suit you way of working? </li></ul></ul></ul><ul><ul><ul><li>Can you pull together or find a consortium? </li></ul></ul></ul><ul><ul><li>Funding is highly competitive, prepare to be disappointed </li></ul></ul><ul><ul><li>Do you want to lead a project? (Time/resource) </li></ul></ul><ul><ul><li>Is the level of funding appropriate? </li></ul></ul><ul><ul><li>Can you wait 1 year for the money? </li></ul></ul>
    • 18. Key Tips <ul><li>Competition is fierce – must be well over the threshold to succeed </li></ul><ul><li>Remember the European aspect </li></ul><ul><li>Read the call carefully – seek 2 nd and 3 rd opinions on topic fit </li></ul><ul><li>Write simply and clearly – don’t assume expert knowledge </li></ul><ul><li>Make time to do a good job – avoid last minute submissions </li></ul><ul><li>Seek help early on </li></ul>
    • 19. Support and Further Information
    • 20. <ul><li>Informing and Awareness Raising </li></ul><ul><ul><li>Call documents and supporting information </li></ul></ul><ul><ul><li>Website and printed newsletters, e-bulletins </li></ul></ul><ul><ul><li>Promotional activities – info days, seminars, </li></ul></ul><ul><ul><li>Signposting – other themes + funding schemes </li></ul></ul><ul><li>Advising and Training </li></ul><ul><ul><li>Helpline – e-mail and telephone enquiries </li></ul></ul><ul><ul><li>Partner search </li></ul></ul><ul><ul><li>Direct support </li></ul></ul><ul><li>Feedback and Signposting </li></ul><ul><ul><li>Problems or difficulties during implementation or participation </li></ul></ul><ul><ul><li>Direct contact with EU Scientific Officers </li></ul></ul><ul><ul><li>Identifying and communicating other areas of support and funding </li></ul></ul>NCP Support All advice is impartial, confidential and free
    • 21. Support and Further Information <ul><li>Website https://ktn.innovateuk.org/web/fp7uk </li></ul><ul><li>E mail [email_address] </li></ul><ul><li>Phone 01302 322633 </li></ul><ul><li>Mobile 07775 584028 </li></ul><ul><li>Alternative </li></ul><ul><li>[email_address] </li></ul><ul><li>+44 (0)20 7395 2205 </li></ul>
    • 22. Framework Programme 7 2012 Call Information Graham Hughes, FP7UK NCP for Health (Industry)
    • 23. 2012 Call – Context <ul><li>Innovation Union </li></ul><ul><li>research and innovation are key drivers of competitiveness, jobs, sustainable growth and social progress. </li></ul><ul><li>More topics targeting knowledge generation to deliver innovative products, processes and services. </li></ul><ul><li>Challenge led programme focusing on specific issues </li></ul><ul><li>More emphasis on exploitation issues such as dissemination, IP protection and knowledge generation. </li></ul>
    • 24. 2012 Call – Innovation Driven <ul><li>Challenge driven – fewer areas open, multiple projects in each area. (36 topics total) </li></ul><ul><ul><li>Primary focus is European Innovation Partnership initiative on active and healthy ageing </li></ul></ul><ul><ul><li>Aim to mobilise critical mass of resources and implement coherent set of actions </li></ul></ul><ul><ul><li>Interlinked topics to bring in wide range of inputs </li></ul></ul><ul><li>Balance upstream research and activities closer to market to achieve short and medium-term outcomes </li></ul><ul><ul><li>focus on medical technologies </li></ul></ul><ul><ul><li>address the socio-economic challenge of innovation </li></ul></ul>
    • 25. 2012 Call – Closed Areas <ul><li>1.1 High Throughput Research </li></ul><ul><li>1.3 Suitability, Safety and Efficacy of Therapies* </li></ul><ul><ul><li>2.2.1 Brain and Brain Related Diseases </li></ul></ul><ul><ul><li>2.3.1 Anti Microbial Drug Resistance </li></ul></ul><ul><ul><li>2.3.3 Potentially New and Re-emerging Epidemics </li></ul></ul><ul><ul><li>2.3.4 Neglected Infectious Diseases* </li></ul></ul><ul><ul><li>2.4.1 Cancer </li></ul></ul><ul><ul><li>2.4.2 Cardiovascular Disease </li></ul></ul><ul><li>3.1 Translating the Results of Clinical Research Outcome </li></ul><ul><li>3.3 Health Promotion and Prevention </li></ul><ul><li>4.2 Responding to EU Policy Needs </li></ul>
    • 26. 2012 Call Overview <ul><li>SME Focus – many SME targeted topics and new SME Call </li></ul><ul><li>Active and Healthy Ageing – 9 coordinated topics </li></ul><ul><li>Medical Technologies – feature highly (related to SME focus) </li></ul><ul><li>Other areas of focus: </li></ul><ul><ul><ul><li>Rare Diseases </li></ul></ul></ul><ul><ul><ul><li>Clinical Trials </li></ul></ul></ul><ul><ul><ul><li>Personalised and Regenerative Medicine (inc transplantation) </li></ul></ul></ul><ul><ul><ul><li>Systems Biology and -omics </li></ul></ul></ul><ul><ul><ul><li>HIV/AIDS, Malaria and TB </li></ul></ul></ul><ul><ul><ul><li>Healthcare delivery </li></ul></ul></ul><ul><ul><ul><li>Coordination and Support Activities </li></ul></ul></ul>
    • 27. 2012 Call – SME Focused <ul><li>Two stage submission/evaluation </li></ul><ul><li>Several funded proposals per topic </li></ul><ul><li>Technology/Methods based topics </li></ul><ul><li>Open topic descriptions </li></ul><ul><li>Small – medium sized projects </li></ul><ul><ul><li>€ 3m or €6m EC contribution </li></ul></ul><ul><ul><li>2 – 5 year duration </li></ul></ul><ul><li>SME targeted topics </li></ul><ul><ul><li>10 Minimum 30% of EC contribution to SMEs </li></ul></ul><ul><ul><li>6 Minimum 15% of EC contribution to SMEs </li></ul></ul>&gt; 30% &gt;15%
    • 28. Health Theme Funding 2007 - 2013 Year Total Funding Projects Funded SME Targeted 2 Stage 2007 € 641 million 153 0% 0 2008 € 577 million 172 0% 0 2009 € 611 million 105 0% 0 2010 € 621 million 131 0% 19% 2011 € 650 million ~126 20% 75% 2012 € 620 million ? 53% 100% 2013 € 780 million ? ~ 50% 100%
    • 29. 2012 Call – Pilot SME Innovation Call <ul><li>3 topics only: </li></ul><ul><ul><li>1,4-2: Medical Technology for transplantation and bioartificial organs </li></ul></ul><ul><ul><li>2.3.0-1: Diagnostics for infectious diseases in humans </li></ul></ul><ul><ul><li>2.4.5-1: Technological approaches to combating sensory impairments </li></ul></ul><ul><li>SMEs have leading role in the project </li></ul><ul><li>&gt;50% EU funding goes to SME partners </li></ul><ul><li># participants limited (3 – 5) </li></ul><ul><li>All partners from EU MS or ACs </li></ul><ul><li>Limits on project duration </li></ul><ul><li>Accelerated evaluation and grant negotiation timeline </li></ul>&gt; 50%
    • 30. 2012 Call – Research Priorities #1 Ageing <ul><li>Must meet Europe 2020 objectives of active and healthy ageing: </li></ul><ul><ul><li>Healthy, active and independent lives until old age </li></ul></ul><ul><ul><li>Ensure the sustainability and efficiency of social and healthcare systems </li></ul></ul><ul><ul><li>Create a European/Global market for innovative products and services related to healthy and active ageing </li></ul></ul><ul><li>11 Topics in call are linked to EIP initiative </li></ul><ul><li>Cross thematic initiative: ICT,KBBE + SSH </li></ul>EIP
    • 31. 2012 Call – Research Priorities #2 Medical Technologies <ul><li>Supporting the “innovation” strategy and closer to market approach </li></ul><ul><li>Large overlap with “SME friendly” topics </li></ul><ul><li>9 topics through the work programme </li></ul>Tech
    • 32. 2012 Call – Research Priorities #3 Clinical Trials <ul><li>Continue the initiative started in the 2011 call for investigator driven clinical trials </li></ul><ul><ul><li>Improve quality of clinical trials data in Europe </li></ul></ul><ul><ul><li>Strengthen CTs in Europe in areas with unmet medical needs </li></ul></ul><ul><li>Funding for Stage II,III or IV clinical trials as RTD activities (i.e. 75% EC contribution). Flexibility w.r.t. duration and participation. </li></ul><ul><li>Involvement of patient groups encouraged </li></ul><ul><li>Outsourcing possible </li></ul><ul><ul><li>Subcontracted third party </li></ul></ul><ul><ul><li>Reimbursement on cost basis </li></ul></ul>Clin
    • 33. 1.2: Detection, Diagnosis and Monitoring EIP &gt; 30% <ul><li>Support R&amp;D and/or proof of principle of technologies for application in the area of personalised medicines </li></ul><ul><ul><li>Tailored medical interventions </li></ul></ul><ul><ul><li>More effective </li></ul></ul><ul><ul><li>Fewer undesirable side effects </li></ul></ul><ul><li>Technologies should be of use for research, screening, diagnostics and/or guidance on therapeutic interventions </li></ul>1.2.1 Development of technologies with a view to patient group stratification for personalised medicine applications 6,000,000 &gt;1
    • 34. 1.4: Innovative Therapeutic Approaches and Interventions &gt;15% &gt;15% EIP &gt; 50% &gt; 30% Tech Tech * 1.4-3 requires cooperation with Australia Clin Transplantation topics have not featured highly in FP7 to date 1.4-1 Innovative approaches to solid organ transplantation 6,000,000 &gt;1 1.4-2 Medical technology for the transplantation sector and bioartificial organs 6,000,000 &gt;1 1.4-3* Innovative strategies for translation of stem cell based therapies in regenerative medicine 6,000,000 1 1.4-4 Targeted nucleic acid delivery as an innovative therapeutic or prophylactic approach 6,000,000 &gt;1
    • 35. 2.1.1: Large Scale Data Gathering &gt;15% EIP &gt; 30% &gt; 30% <ul><li>Objective is to use high-throughput technologies to generate data for elucidating the function of genes and gene products. </li></ul><ul><li>Topics focus on the clinical use of –omics approaches and analysis of their outcomes. </li></ul>2.1.1.1-A Support for international rare disease research 2,000,000 1 2.1.1.1-B Clinical utility of -omics for better diagnosis of rare diseases 12,000,000 2 2.1.1.1-C Databases, biobanks and clinical bio-informatics&apos; hub for rare diseases 12,000,000 1 2.1.1-2 Validation of -omics based biomarkers for diseases affecting the elderly 12,000,000 &gt;1 2.1.1-3 Statistical methods for collection and analysis of -omics data 6,000,000 &gt;1
    • 36. 2.1.2: Systems Biology <ul><li>medical needs should drive systems biology research </li></ul><ul><li>using systems medicine to improve understanding of disease mechanisms, prognosis and diagnosis of common diseases </li></ul><ul><li>Coordinate European research activities for systems biology applications to medicine </li></ul>&gt; 30% 2.1.2-1 Systems medicine: SME-driven research applying systems biology approaches to address clinical needs 3,000,000 &gt;1 2.1.2-2 Systems medicine: Applying systems biology approaches for understanding common human diseases and their co-morbidities 12,000,000 &gt;1 2.1.2-3 Preparing for the future research and innovation activities in systems medicine 3,000,000 1
    • 37. 2.2.2: Human Development and Ageing &gt;15% EIP EIP Clin &gt; 30% <ul><li>Focus on use and application of –omics knowledge and tools to gain a clear understanding of the fundamental mechanisms of human ageing </li></ul><ul><li>Clinical trials should compare outcomes of various treatment regimens </li></ul>2.2.2-1 Integrative systems biology and comparative genomics for studying human ageing and most common age-related conditions 6,000,000 &gt;1 2.2.2-2 Investigator-driven clinical trials for optimisation of treatment for elderly patients with multiple diseases 6,000,000 &gt;1
    • 38. 2.3.0: Cross Cutting &gt; 50% Tech <ul><li>SMEs should take a leading role in 2.3.0-1 </li></ul><ul><li>Project should be &lt; 3 years </li></ul><ul><li>€ 6,000,000 ceiling is max only </li></ul><ul><li>ERA-NET should deepen and extend the coordination of European research in infectious diseases and be complementary to other European activities in this area. </li></ul>2.3.0-1 Diagnostics for infectious diseases in humans 6,000,000 &gt;1 2.3.0-2 ERA-NET on Infectious Diseases 2,000,000 1
    • 39. 2.3.2: HIV/AIDS Malaria and TB <ul><li>Co-infection and co-morbidity of HIV and other common infectious diseases poorly understood </li></ul><ul><li>Prevention topic is looking for small, rapid projects </li></ul><ul><ul><li>1 – 3 years, €1 – 6 million funding </li></ul></ul><ul><li>Low cost interventions looking for solutions that can be implemented within the project period </li></ul>&gt;15% 2.3.2-1 Co-infection and co-morbidity in HIV/AIDS, malaria, tuberculosis and/or hepatitis 6,000,000 &gt;1 2.3.2-2 Co-morbidity between infectious and non-communicable diseases 6,000,000 &gt;1 2.3.2-3 Prevention and treatment for HIV/AIDS, malaria and tuberculosis 6,000,000 &gt;1 2.3.2-4 Low-cost interventions for disease control in resource poor settings 3,000,000 &gt;1
    • 40. 2.4.3: Diabetes and Obesity Clin &gt; 30% Tech 2.4.3-1 Innovative approach to manage diabetes 6,000,000 &gt;1 2.4.3-2 Investigator-driven clinical trials for type 1 diabetes research 6,000,000 &gt;1
    • 41. 2.4.4: Rare Diseases Clin Clin &gt; 30% 2.4.4-1 Preclinical and/or clinical development of substances with a clear potential as orphan drugs 6,000,000 &gt;1 2.4.4-2 Observational trials in rare diseases 3,000,000 &gt;1 2.4.4-3 Best practice and knowledge sharing in the clinical management of rare diseases 2,000,000 1
    • 42. 2.4.5: Other Chronic Diseases EIP &gt; 50% &gt;15% EIP Tech Tech 2.4.5-1 Technological approaches to to combating sensory impairments 6,000,000 &gt;1 2.4.5-2 Biomarkers and diagnostics for chronic inflammatory diseases of the joints 6,000,000 &gt;1
    • 43. 2012 Call – Healthcare Delivery <ul><li>Addressing the need for systematic mapping of variations in health care practice and standardisation of health technology assessment </li></ul><ul><li>Various areas of healthcare covered </li></ul><ul><li>EU has strong political stance on healthcare equality </li></ul>EIP EIP Tech 3.2-1 Improving the organisation of health service delivery 3,000,000 &gt;1 3.2-2 New methodologies for health technology assessment 3,000,000 &gt;1 3.2-2 Social Innovation platform for ageing research 6,000,000 1 3.4-1 Health systems/services research in low and middle income countries 6,000,000 &gt;1
    • 44. 2012 Call – Coordination and Support Actions <ul><li>Various actions to complement research activities, develop infrastructure and determine future activities </li></ul>4.1-1 Network to encourage technology transfer in FP-funded health research (especially in academic and governmental organisations) 2,000,000 1 4.1-2 Training actions linked to intellectual property rights management and technology transfer 2,000,000 1 4.1-3 Support for Presidency events: Organisation of supporting actions and events related to the Presidency of the European Union 100,000 &gt;1 4.1-4 Communicating the benefits of European research to the general public 1,000,000 &gt;1 4.1-5 Preparing for the future for health research and innovation 500,000 &gt;1
    • 45. <ul><li>09 June 2011: Open Info Day, Brussels </li></ul><ul><li>10 June 2011: Brokerage Event, Brussels </li></ul><ul><li>20 July 2011: Call Opens – EPSS available </li></ul><ul><li>27 Sept 2011: likely Stage 1 deadline (INNOVATION 2) </li></ul><ul><li>04 Oct 2011: likely Stage 1 deadline (INNOVATION 1) </li></ul><ul><li>Dec 2011: Stage 1 notification </li></ul><ul><li>Feb 2012: Stage 2 deadline </li></ul>Key Dates
    • 46. Other Health Related EU Funding Sources 2011 Nanosciences, Materials and Production NMP NMP.2012.1.2-2: Development and phase-I clinical trials of novel therapeutic nanotechnology-enabled systems for the diagnosis and treatment of atherosclerosis NMP.2012.2.2-1: Biomaterials for improved performance of medical implants Likely timeframe similar to Health call
    • 47. Other Health Related EU Funding Sources 2011 <ul><li>ICT call </li></ul><ul><li>Virtual Physiological Human </li></ul><ul><li>E-health and data management </li></ul><ul><li>KBBE call </li></ul><ul><li>Research For the Benefit of SMEs </li></ul><ul><li>Call opens July 2011 </li></ul><ul><li>Ambient Assisted Living </li></ul><ul><li>ICT based solutions for Advancement of Older Persons’ Mobility </li></ul><ul><li>Call opened 31 March 2011, deadline 30 June 2011 </li></ul>

    ×